<DOC>
	<DOCNO>NCT01552668</DOCNO>
	<brief_summary>The purpose research study evaluate effectiveness antibiotic call fidaxomicin preventing C. difficile infection .</brief_summary>
	<brief_title>Fidaxomicin Prevent Clostridium Difficile Colonization</brief_title>
	<detailed_description>A novel approach prevent C. difficile infection use compound activity C. difficile primary prophylaxis high risk patient . Chemoprophylaxis theoretically prevent C. difficile infection two mechanism . It may reduce transmission asymptomatic C. difficile carrier reduce number spore shed stool prevent replication subsequent toxin production organism patient risk C. difficile infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<criteria>â‰¥ 18 year old On broad spectrum antimicrobial Anticipated length stay &gt; 48 hour enrollment A nonICU inpatient Pregnant Expected die within 7 day Have previously enrol trial trial investigational agent treat CDI , and/or monotherapy antimicrobial generally consider increase risk CDI ( vanc , macrolides , tetracycline , trimethoprim/sulfamethoxazole , aminoglycosides , colistin , linezolid , nitrofurantoin , metronidazole )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Clostridium difficile infection</keyword>
	<keyword>fidaxomicin</keyword>
</DOC>